TRANSPERS News: 2024 in Review and Two JAMA Publications Generate Wide Interest

Tue Feb 11, 2025

Letter from Center Director

Dear Colleagues:

Happy 2025! I’d like to thank the TRANSPERS team for a productive 2024, and I’m excited to continue our work in 2025. This newsletter highlights several impactful publications, collaborators in the news, a congratulations, and conference highlights.

Do you have an announcement you would like to see in our next newsletter? Let us know!

Kathryn

Year in Review: 2024

 

 

 

 

 

What's Coming Up: 2025

In 2025, we are continuing our work on:

  • Expedited Regulatory Approval Pathways for Drugs and Diagnostics
  • Model-based Outcomes for Geographic-based Health Outcomes
  • Cost-effectiveness Across Different Populations
  • Role of Independent Medical Review for Genetic Tests
  • Financial Assistance Programs for Patients

2024 JAMA Publication On Blood Tests for Alzheimer’s Disease Generates Broad Interest

A recent JAMA publication by TRANSPERS collaborators Patricia A. Deverka, Grace A. Lin, and Kathryn A. Phillips addresses payer coverage considerations for an emerging technology: new blood tests for Alzheimer’s disease. The article has almost 10,500 social media views and was featured in the recent UCSF Precision Medicine and UCSF Institute for Health Policy Studies newsletters, which reflect this issue's timeliness and importance.

TRANSPERS Work on Multicancer Detection Tests Continues to be Widely Disseminated

Our work on coverage considerations for multicancer detection tests is in the top 1% for Almetric scores across all journals for that timeframe, illustrating that this work continues to generate wide interest across news and social media outlets.

TRANSPERS In the News

TRANSPERS collaborator Emily Mrig was featured by the UCSF School of Pharmacy in an article that described her work on using artificial intelligence tools to identify solutions that make molecular diagnostics more accessible and affordable for patients who have  advanced non-small cell lung cancer.

 

 

Long-time TRANSPERS colleague Allison Kurian was interviewed for an article in the Washington Post about genetic testing and its importance for cancer prevention, testing, and treatment.

Grace Lin was cited in a Council of State Governments Midwest story on states mandating that health plans cover biomarker testing, a topic Lin knows well and wrote about in a 2024 paper published in JAMA.

TRANSPERS Collaborator Deborah Marshall Receives Award

TRANSPERS Scientific Advisory Board member Deborah Marshall was honored with the Marilyn Dix Smith Leadership Award at ISPOR 2024 and recognized for her leadership in the field of health economics and outcomes research. Congratulations Deborah!

 

Conference Highlights: ISPOR 2024 and ACMG 2025

TRANSPERS colleague Jeroen Jansen taught courses on cost-effectiveness modeling in R and network meta-analysis and served as a panelist at ISPOR conferences (ISPOR 2024, ISPOR Europe 2024).

 

 

Join Emily Mrig at the 2025 ACMG Annual Clinical Genetics Meeting where she’ll present on “Participants' Experiences with and Perspectives on Genomic Research in an Undiagnosed Disease Program.” Register here.

Keywords

Newsletters